The human immunodeficiency virus (HIV) is the causative agent of acquired immunodeficiency syndrome (AIDS).

Drug-resistance is a critical factor contributing to the gradual loss of clinical benefit to treatments for HIV infection. Accordingly, combination therapies have further evolved to address the mutating resistance of HIV. However, there has been great concern regarding the apparent growing resistance of HIV strains to current therapies.

The subject invention provides for treatment and prevention of HIV infection and/or AIDS. The invention provides for 2,5- diamino-3,4-disubstituted-1,6- diphenylhexane (DAD) isosteres comprising benzamide, sulfonamide, and anthranilamide subunits; a pharmaceutical composition comprising such compounds; a method of using such compounds to treat retroviral, specifically HIV and more specifically HIV-1 and HIV-2, infections in mammals, particularly humans; a method of synthesizing asymmetric DAD isosteres comprising benzamide, sulfonamide, and anthranilamide subunits; and a method of using such compounds to assay new compounds for antiretroviral activity.

Inventors:

Ramnarayan S. Randad and John W. Erickson (NCI)

U.S. Patent 5,728,718 issued 17 Mar 1998 (DHHS Reference No. E-240-1994/0-US-01);

U.S. Patent 5,925,780 issued 20 Jul 2000 (DHHS Reference No. E-240-1994/0-US-07);

U.S. Patent 6,066,656 issued 23 May 2000 (DHHS Reference No. E-240-1994/0-US-08)

Licensees sought